Bris­tol My­ers and 2sev­en­ty bio say FDA de­layed CAR-T ther­a­py de­ci­sion

The FDA is de­lay­ing its de­ci­sion on whether to ap­prove Bris­tol My­ers Squibb and 2sev­en­ty bio’s CAR-T cell ther­a­py for mul­ti­ple myelo­ma in ear­li­er lines of treat­ment, and it plans to hold a pub­lic meet­ing with out­side ex­perts to dis­cuss.

The reg­u­la­tor was orig­i­nal­ly ex­pect­ed to make a de­ci­sion by Dec. 16 on whether to ap­prove Abec­ma for mul­ti­ple myelo­ma in adults whose can­cer re­turned af­ter al­ready re­ceiv­ing two to four pri­or reg­i­mens. Cur­rent­ly, the drug is ap­proved for mul­ti­ple myelo­ma pa­tients who have pre­vi­ous­ly had four or more lines of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER